PatrickFordeMD

Oncology • Baltimore, MD

Thoracic Cancer

Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Forde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Forde's full profile

Already have an account?

Office
300 Mason Lord Drive
Kimmel Cancer Center
Baltimore, MD 21224
Phone+1 410-550-1711

Fax+1 410-550-1116

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Royal College of Surgeons IrelandClass of 2004

Certifications & Licensure

MD State Medical License 2014 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Start of enrollment: 2015 Nov 23
Terminated
Phase 1, Phase 2
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Start of enrollment: 2017 Jun 13
Completed
Phase 2
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Start of enrollment: 2017 Dec 12
Active, not recruiting
Phase 2
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Start of enrollment: 2019 Oct 02
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

[F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy.
Jelena Levi, Millie Das, Minal S Vasanawala, Deepti Behl, Martin Pomper
Journal of Nuclear Medicine. 2024-12-03
Divergent clinical and immunologic outcomes based on STK11 co-mutation status in resectable KRAS-mutant lung cancers following neoadjuvant immune checkpoint blockade.
Samuel Rosner, Sydney Connor, Khaled Sanber, Marianna Zahurak, Tianbei Zhang
Clinical Cancer Research. 2024-11-15
2 citations
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01

Journal Articles

Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Elad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research

Press Mentions

Year in Review: Non-Small Cell Lung CancerNovember 1st, 2024
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLCSeptember 9th, 2024
Exploratory Data Support Both Adjuvant and Neoadjuvant Nivolumab for NSCLCSeptember 9th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/patrick-forde